Low Cholesterol due to APOB Variants: Exploring the Balance Between Liver and Cardiovascular Risk.

ABSTRACT:

Background & aims

Lifelong APOB gene inactivation lowers LDL-C and cardiovascular risk, but impairs hepatic lipoprotein export, predisposing to chronic liver disease (CLD). The extent to which common steatogenic factors modulate this risk remains unclear. Moreover, the balance between long-term cardiovascular protection and CLD risk in APOB variant carriers has never been evaluated.

Methods

Using UK Biobank data, we analysed 241 APOB loss-of-function (LoF) carriers and 410 721 non-carriers, stratified by steatogenic risk factors, including age, sex, diabetes, BMI, alcohol intake and the PNPLA3-rs738409 genotype. Associations with transaminase levels, CLD and cardiovascular (ASCVD) outcomes were assessed using Python and R packages.

Results

APOB carriers had ~35% lower

SUBMITTER: Di Costanzo A 

PROVIDER: S-EPMC12813735 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature